Pluronic-attached polyamidoamine dendrimer conjugates overcome drug resistance in breast cancer

Nanomedicine (Lond). 2016 Nov;11(22):2917-2934. doi: 10.2217/nnm-2016-0252. Epub 2016 Oct 26.

Abstract

Aim: To design pluronic F68 (PF68)-conjugated polyamidoamine (PAMAM) dendrimer conjugates for doxorubicin (DOX) delivery for overcoming multidrug resistance, and clarify the reversal mechanism.

Materials & methods: A series of PAMAM-PF68 conjugates were designed. The antitumor activity of the DOX-loaded conjugates was evaluated against MCF-7/ADR cells, tumor spheroids and tumors. Several bioinformatics were detected to characterize the reversal mechanism.

Results: Increased antitumor activity of the DOX-loaded conjugates was achieved in vitro and in vivo. The complexes induced more DOX accumulation via caveolae-mediated endocytosis. After escaping from the endosome/lysosome, the nuclear trafficking of DOX was achieved. Apoptosis was significantly increased by regulating mitochondrial function and gene expression.

Conclusion: With optimized PF68 modification, PAMAM-PF68 conjugates can significantly overcome multidrug resistance in vitro and in vivo.

Keywords: PAMAM dendrimer; cancer treatment; drug resistance; mechanism; pluronic.

MeSH terms

  • Apoptosis / drug effects*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Dendrimers / administration & dosage
  • Dendrimers / chemistry*
  • Doxorubicin / administration & dosage
  • Doxorubicin / chemistry
  • Drug Resistance, Neoplasm / drug effects*
  • Female
  • Humans
  • MCF-7 Cells
  • Polyamines / administration & dosage
  • Polyamines / chemistry

Substances

  • Dendrimers
  • Poly(amidoamine)
  • Polyamines
  • Doxorubicin